




PHARMACEUTICAL 2021

NeuBase Therapeutics Inc.
Rank 101 of 402





PHARMACEUTICAL 2021

NeuBase Therapeutics Inc.
Rank 101 of 402

The relative strengths and weaknesses of NeuBase Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NeuBase Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 82% points. The greatest weakness of NeuBase Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 194%, being 146% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	32,809
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	0
Liabilities, Non-Current	0
Other Assets	469
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	3,150
Other Net Income	-315
Other Revenues	0
Property and Equipment	1,167
Research and Development	6,946
Selling, General and Administrative Expense	10,123

Output Variable	Value in 1000 USD
Assets	34,444
Liabilities	3,150
Expenses	17,069
Revenues	0
Stockholders Equity	31,295
Net Income	-17,385
Comprehensive Net Income	-17,385
Economic Capital Ratio	194%